Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
Mi | Pharming Group N.V.: Pharming Group to report first quarter 2024 financial results on May 8 | 128 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results... ► Artikel lesen | |
Mi | Pharming Group N.V.: Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards | 3 | GlobeNewswire (USA) | ||
19.04. | Pharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 | 696 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Leiden... ► Artikel lesen | |
18.04. | Pharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029 | 302 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Leiden... ► Artikel lesen | |
18.04. | Pharming Group N.V.: Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 | 212 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Pharming... ► Artikel lesen | |
08.04. | Pharming Group N.V.: Pharming announces completion of enrollment in pediatric clinical trial of leniolisib | 159 | GlobeNewswire (Europe) | This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group... ► Artikel lesen | |
04.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
04.04. | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
04.04. | Pharming Group N.V.: Pharming Group announces the 2024 Annual General Meeting of Shareholders | 2 | GlobeNewswire (USA) | ||
04.04. | Pharming Group N.V.: Pharming Group announces the filing of its 2023 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
15.03. | Pharming reports Q4 results | 4 | Seeking Alpha | ||
15.03. | Earnings call: Pharming Group N.V. sees steady growth with RUCONEST and Joenja | 6 | Investing.com | ||
14.03. | Pharming Group slips on 2023 net loss, 'weak' guidance | 7 | Reuters | ||
14.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
14.03. | Pharming Group Q4 Loss Narrows - Update | 1 | RTTNews | ||
14.03. | Pharming Group NV reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
14.03. | Pharming Group N.V.: Pharming Group reports fourth quarter and full year 2023 financial results | 84 | GlobeNewswire (Europe) | Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1... ► Artikel lesen | |
29.02. | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14 | 257 | GlobeNewswire (Europe) | Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year... ► Artikel lesen | |
08.02. | Pharming Group N.V.: Pharming Group to participate in February investor conferences | 367 | GlobeNewswire (Europe) | Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INTELLIA THERAPEUTICS | 20,550 | +0,15 % | Intellia Therapeutics, Inc.: Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 | ||
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,515 | +1,16 % | APEV, PACB and BILI are among premarket gainers | ||
CENTOGENE | 0,442 | +1,61 % | Centogene NV: CENTOGENE Receives Nasdaq Non-Compliance Notice | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) ("Centogene", "we", or the "Company"), the essential life science partner for data-driven... ► Artikel lesen | |
ATAI LIFE SCIENCES | 1,874 | +1,74 % | atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights | Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003... ► Artikel lesen | |
BIOMERIEUX | 102,50 | +0,10 % | Biomerieux shares eye best day in 25 mths after better-than-expected Q1 | ||
CYCLACEL | 1,460 | 0,00 % | Cyclacel Pharmaceuticals, Inc. - 10-K/A, Annual Report | ||
SYROS PHARMACEUTICALS | 4,760 | -4,80 % | Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies... ► Artikel lesen | |
GENUS | 19,700 | +1,55 % | Dividendenbekanntmachungen (29.02.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,14 USD 0,1291 EUR AGNICO EAGLE MINES LIMITED CA0084741085 0,4 USD 0,369 EUR ALLIANCE... ► Artikel lesen | |
XTL BIOPHARMACEUTICALS | 2,220 | +1,83 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
ATRECA | 0,155 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.03.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 28.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.03.2024ISIN NameGB00BZ2JBG28 REACT... ► Artikel lesen | |
ANAPTYSBIO | 19,900 | +2,05 % | AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial... ► Artikel lesen | |
ABIONYX PHARMA | 0,949 | -1,25 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
MEIRAGTX | 4,380 | +1,86 % | MeiraGTx to Participate in Upcoming Investor Conferences | ||
METABOLIC EXPLORER | 0,140 | +3,70 % | XFRA 7ME: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
AKESO | 5,800 | 0,00 % | AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF 2023 ANNUAL REPORT |